Nurix Reports Positive Results For BTK Degrader NX-5948 In Waldenstrom’s Macroglobulinemia
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally bioavailable, brain-penetrant degrader of Burton’s tyrosine kinase or BTK, in patients with relapsed/refractory Waldenström’s macroglobuli
:max_bytes(150000):strip_icc():format(jpeg)/sign-reading-for-sale-by-owner-outside-single-family-home-200256006-001-579798553df78ceb8672372a.jpg)
" title=":max_bytes(150000):strip_icc():format(jpeg)/GettyImages-111661701-fc3fd2dede3f4574866dba051b67473a.jpg "How an All-Cash Offer Can Help You Win a Bidding War")
